NCT00240877 - Study to Evaluate the Safety of a Monovalent Vaccine of a New 6:2 Reassortant in Healthy Adults (AV024) | Biotech Hunter

Enrollment

330

Participants

Timeline

Start Date

August 31, 2002

Primary Completion Date

August 31, 2003

Study Completion Date

April 30, 2004

Conditions

Influenza

Interventions

BIOLOGICAL

AV024

0.5 mL total dose volume administered intranasal by spray applicator (approximately 0.25 mL into each nostril).

OTHER

Placebo

Placebo mist consisting of normal allantoic fluid. 0.5 mL total dose volume administered intranasal by spray applicator (approximately 0.25 mL into each nostril).

Trial Locations (1)

33181

SFBC International Inc, Miami